RPCEC00000214尚未招募1 期
Co-administration of EGF and GHRP-6 in patients with acute cerebral infarction of ischemic etiology.
Center for Genetic Engineering and Biotechnology (CIGB), in Havana0 个研究点目标入组 30 人开始时间: 2016年5月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •1. Compliance with the diagnostic criteria (patients of both sexes with a focal neurologic defects caused by disturbances in blood supply to a particular brain area).
- •2. Age between 18 and 80 years, including both.
- •3. Time between onset of symptoms and start of administration of CIGB-845 less than 12 hours.
- •4. Willingness of the patient (or family) through the granting of informed consent (oral). In a second moment (once the patient is stabilized) the investigator must obtain the written consent of the patient, who may freely decide whether to accept or not to continue the investigation.
排除标准
- •1. Coma (Glasgow Coma Scale less than 8).
- •2. Points in the NIHSS <5 or> 20 scale.
- •3. When the neurological defect can be explained by a different entity to ICA.
- •4. Patients with neurological symptoms or signs return to normal before treatment begins.
- •5. Severe uncontrolled hypertension (systolic> 185 mm Hg or diastolic BP> 110 mm Hg) not descend after treatment.
- •6. Low blood pressure (systolic <95 mm Hg) unresponsive to standard therapy.
- •7. Method of installation box with seizures.
- •8. Patients diagnosed with malignancies.
- •9. Pregnancy or breastfeeding at the time of inclusion in the study (reported by the patient or family).
- •10. Mental incapacity obvious to issue consent and act accordingly to the study.
研究者
相似试验
尚未招募
3 期
COURAGE-2 StudyAcute cerebral infarction of ischemic etiologyBrain InfarctionBrain IschemiaCerebrovascular DisordersVascular DiseasesCardiovascular DiseasesBrain DiseasesCentral Nervous System DiseaseNervous System DiseasesStrokeCerebral InfarctionRPCEC00000300Center for Genetic Engineering and Biotechnology (CIGB), in Havana220
进行中（未招募）
不适用
Effects of growth hormone treatment to patients with partial growth hormone deficiency, with special emphasis on acute phase proteins and pro-inflammatory cytokines.EUCTR2005-004478-26-SEKarolinska universitetssjukhuset
招募中
2 期
Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment (PACE-Lung)2024-517965-18-00Goethe University Frankfurt, Goethe University Frankfurt400
暂停
2 期
Panitumumab as second line therapy for advanced pancreatic ductal adenocarcinoma with wild-type KRAS geneKRAS wild-type unresectable or metastatic pancreatic ductal adenocarcinomaCancer - PancreaticACTRN12617000540314Dr Daniel Croagh24
进行中（未招募）
不适用
Growth hormone and androgens in the treatment of glucocorticoid induced protein catabolism - GH and androgens in protein catabolismChronic treatment with glucocorticoids (GCs) regardless of indication leads to marked protein catabolism that causes substantial debilitation which includes muscle wasting, weakness, skin fragility, bruising, poor wound healing and osteoporosis. The selection of subjects is therefore patients with polymyalgia rheumatica or inflammatory arthitis receiving long-term GC treatment.EUCTR2005-003750-10-SEVästraGötaland12